F
Francois Lassailly
Researcher at London Research Institute
Publications - 21
Citations - 1971
Francois Lassailly is an academic researcher from London Research Institute. The author has contributed to research in topics: Myeloid leukemia & Stem cell. The author has an hindex of 13, co-authored 21 publications receiving 1662 citations. Previous affiliations of Francois Lassailly include Lincoln's Inn & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress
Zachary T. Schug,Barrie Peck,Dylan T. Jones,Qifeng Zhang,Shaun E. Grosskurth,Israt S. Alam,Louise Goodwin,Elizabeth Smethurst,Susan M. Mason,Karen Blyth,Lynn McGarry,Daniel James,Emma Shanks,Gabriela Kalna,Rebecca E. Saunders,Ming Jiang,Michael Howell,Francois Lassailly,May Zaw Thin,Bradley Spencer-Dene,Gordon Stamp,Niels J. F. van den Broek,Gillian M. Mackay,Vinay Bulusu,Jurre J. Kamphorst,Saverio Tardito,David P. Strachan,Adrian L. Harris,Eric O. Aboagye,Susan E. Critchlow,Michael J.O. Wakelam,Almut Schulze,Eyal Gottlieb +32 more
TL;DR: A critical role for acetate consumption in the production of lipid biomass within the harsh tumor microenvironment is concluded, indicating a critical role in the growth of cancer cell growth under low-oxygen and lipid-depleted conditions.
Journal ArticleDOI
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Madhu S. Kumar,David C. Hancock,Miriam Molina-Arcas,Michael Steckel,P East,Markus E. Diefenbacher,Elena Armenteros-Monterroso,Francois Lassailly,Nik Matthews,Emma Nye,Gordon Stamp,Axel Behrens,Julian Downward,Julian Downward +13 more
TL;DR: It is shown that RAS-pathway mutant NSCLC cells depend on the transcription factor GATA2, and discovery of the nononcogene addiction of KRAS mutant lung cancers to Gata2 presents a network of druggable pathways for therapeutic exploitation.
Journal ArticleDOI
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
Irene Pizzitola,Fernando Anjos-Afonso,Kevin Rouault-Pierre,Francois Lassailly,Sarah Tettamanti,Orietta Spinelli,Andrea Biondi,Ettore Biagi,Dominique Bonnet +8 more
TL;DR: It is shown that both these modified T cells are very efficient in reducing leukemia burden in vivo, but only the anti-CD123 CAR has limited killing on normal HSPCs, thus making it a very attractive immunotherapeutic tool for AML treatment.
Journal ArticleDOI
Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia
Diana Passaro,Alessandro Di Tullio,Ander Abarrategi,Kevin Rouault-Pierre,Katie Foster,Linda Ariza-McNaughton,Beatriz Montaner,Probir Chakravarty,Leena Bhaw,Giovanni Diana,Francois Lassailly,John G. Gribben,Dominique Bonnet +12 more
TL;DR: A detailed picture of the BM vasculature in acute myeloid leukemia using intravital two-photon microscopy is provided and inhibition of NO production reduced vascular permeability, preserved normal hematopoietic stem cell function, and improved treatment response in PDX.
Journal ArticleDOI
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano,Clare Sheridan,May Zaw Thin,Emma Nye,Bradley Spencer-Dene,Markus E. Diefenbacher,Christopher Moore,Madhu S. Kumar,Miguel M. Murillo,Miguel M. Murillo,Eva Grönroos,Francois Lassailly,Gordon Stamp,Julian Downward,Julian Downward +14 more
TL;DR: The need for RAS interaction with p110α in the maintenance of mutant Kras-driven lung tumors was explored using an inducible mouse model and a tumor cell-autonomous effect was improved significantly by combination with MEK inhibition.